NCT00572637View on ClinicalTrials.gov

Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Solid TumorsLymphoma, Non-Hodgkin
Interventions
DRUG

CEP-18770

Administered as intravenous infusion on days 1, 4, 8, and 11 of a 21-day cycle up to 6 cycles. Starting dose 0,1 mg/sqm

Trial Locations (3)

6500

IOSI - Oncology Institute of Southern Switzerland - Ospedale S. Giovanni, Bellinzona

9007

Kantonsspital St. Gallen, Sankt Gallen

20141

Europen Institute of Oncology, Milan

Sponsors
All Listed Sponsors
lead

Ethical Oncology Science

INDUSTRY